HIV 치료제 시장 규모, 점유율, 동향 및 예측 : 약제 클래스별, 유통 채널, 지역별(2026-2034년)

The global HIV drugs market size was valued at USD 34.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 45.8 Billion by 2034, exhibiting a CAGR of 3.27% during 2026-2034. North America currently dominates the market, holding a significant market share of over 45.7% in 2025 . The HIV drugs market share is experiencing steady growth due to the increasing awareness and prevention efforts, growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

Various organizations are identifying the significance of leveraging vast volumes of structured and unstructured data to make decisions, enhance customer experience, and enhance operations. Growing use of big data, innovations in AI and machine learning technologies, and broadening use areas of cloud computing have further increased this trend. Additionally, increased demand for data-driven decision-making across various industries is driving the HIV drugs demand. Besides, the growth in digital transformation projects and the demand for real-time analytics to respond to competitive pressures and changing market needs are the major drivers of the growth of the market.

The United States stands out as a key market disruptor, driven by widespread digital transformation initiatives across diverse sectors where analytics is pivotal for operational optimization and strategic planning. The increasing initiatives for implementing advanced technologies in the defense sector are opening new growth avenues for the HIV drugs market growth. For instance, in July 2024, The United States Department of Defense signed a Statement of Intent (SOI) for data, analytics, and artificial intelligence cooperation with the Singapore Ministry of Defense. The SOI deploys a holistic method for technological collaboration, allowing both defense establishments to examine approaches and discuss the best practices for leveraging data, analytics, and AI capabilities at speed and scale.

HIV DRUGS MARKET TRENDS:

Growing Prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021, according to an industry report. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in Treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences. For example, in 2024, Gilead shared complete Phase 3 PURPOSE 2 trial results on twice-yearly lenacapavir for HIV prevention at HIV Glasgow. The research demonstrated lenacapavir lowered HIV infections by 96%, beating Truvada. These developments increase treatment effectiveness and also enhance patient compliance, underpinning ongoing HIV drugs market growth.

Increasing Awareness Among Patients

Rising awareness and diagnostic rates among patients represent the primary factor driving the HIV drugs market. In India, for instance, the National AIDS Control Programme (NACP) conducted approximately 48 million HIV tests in the 2020-21 period, including 24.8 million tests among pregnant women. In the first six months of 2022-23, around 31 million HIV tests were undertaken, with projections indicating that more than 60 million tests would be conducted during the entire 2022-23 period-the highest since the program's inception. This increase in testing has led to a rise in the number of individuals diagnosed and subsequently seeking treatment. As of September 2022, approximately 1.624 million people living with HIV (PLHIV) in India were on antiretroviral (ARV) treatment, an increase of 110,000 from the previous year. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising Focus on Combination Therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. Gilead Sciences, a leading pharmaceutical company, reported robust sales of its combination therapy, Biktarvy. In the fourth quarter of 2024, Biktarvy achieved sales of USD 3.8 billion, marking a 21% increase from the previous year. This growth contributed to Gilead's total HIV drug revenue of USD 7.6 billion for the quarter. The growing preference for combination therapies among healthcare providers and patients is a key factor providing a positive HIV drugs market outlook.

HIV DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

• Nucleoside Reverse Transcriptase Inhibitors
• Multi-Class Combination Products
• Protease Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Entry Inhibitors - CCR5 Co-Receptor Antagonist
• Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors lead the market with around 43.2% of market share in 2025. NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Hospital pharmacies lead the market with around 49.5% of market share in 2025. Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Regional Analysis:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 45.7%. North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

COMPETITIVE LANDSCAPE:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The report provides a comprehensive analysis of the competitive landscape in the HIV drugs market with detailed profiles of all major companies, including:

• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• ViiV Healthcare
• AbbVie
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• Johnson & Johnson
• Cipla Limited
• Daiichi Sankyo
• Emcure Pharmaceuticals
• Hetero Drugs
• Mylan N.V

Key Questions Answered in This Report

• 1.How big is the HIV drugs market?
• 2.What is the future outlook of HIV drugs market?
• 3.What are the key factors driving the HIV drugs market?
• 4.Which region accounts for the largest HIV drugs market share?
• 5.Which are the leading companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global HIV Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Price Analysis
• 5.5 Market Breakup by Drug Class
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast
• 5.9 SWOT Analysis
  • 5.9.1 Overview
  • 5.9.2 Strengths
  • 5.9.3 Weaknesses
  • 5.9.4 Opportunities
  • 5.9.5 Threats
• 5.10 Value Chain Analysis
  • 5.10.1 Overview
  • 5.10.2 Research and Development
  • 5.10.3 Raw Material Procurement
  • 5.10.4 Manufacturing
  • 5.10.5 Marketing
  • 5.10.6 Distribution
  • 5.10.7 End-Use
• 5.11 Porters Five Forces Analysis
  • 5.11.1 Overview
  • 5.11.2 Bargaining Power of Buyers
  • 5.11.3 Bargaining Power of Suppliers
  • 5.11.4 Degree of Competition
  • 5.11.5 Threat of New Entrants
  • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

• 6.1 Nucleoside Reverse Transcriptase Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-Class Combination Products
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Protease Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 HIV Integrase Strand Transfer Inhibitors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Fusion Inhibitors and Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

• 9.1 Product Overview
• 9.2 Raw Material Requirements
• 9.3 Manufacturing Process
• 9.4 Key Success and Risk Factors

10 Competitive Landscape

• 10.1 Market Structure
• 10.2 Market Breakup by Key Players
• 10.3 Profiles of Key Players
  • 10.3.1 Boehringer Ingelheim International GmbH
  • 10.3.2 Merck & Co., Inc.
  • 10.3.3 ViiV Healthcare
  • 10.3.4 AbbVie
  • 10.3.5 F. Hoffmann-La Roche Ltd.
  • 10.3.6 Teva Pharmaceutical Industries Ltd.
  • 10.3.7 Bristol-Myers Squibb
  • 10.3.8 Gilead Sciences, Inc.
  • 10.3.9 Johnson & Johnson
  • 10.3.10 Cipla Limited
  • 10.3.11 Daiichi Sankyo
  • 10.3.12 Emcure
  • 10.3.13 Hetero Drugs
  • 10.3.14 Mylan